(Q33770374)

English

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

abiraterone acetate

1 reference

ChEBI release 2020-05-28

prostate cancer

1 reference

based on heuristic

inferred from title

Leon Terstappen

13

object named as

Leon W M M Terstappen

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Howard I. Scher

19

object named as

Howard I Scher

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

18

object named as

Eric Small

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Alison H M Reid

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Gerhardt Attard

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Daniel C Danila

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Nikhil Babu Oommen

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

David Olmos

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Peter C Fong

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

L Rhoda Molife

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Joanne Hunt

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Christina Messiou

9

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Christopher Parker

10

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

David Dearnaley

11

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Joost F Swennenhuis

12

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Gloria Lee

14

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Thian Kheoh

15

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Arturo Molina

16

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Charles J Ryan

17

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Johann S de Bono

20

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

16 February 2010

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1489-1495

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Estimates of the cancer incidence and mortality in Europe in 2006.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Aromatase inhibition: translation into a successful therapeutic approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

The androgen axis in recurrent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Planned versus attained design in phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

4 July 2018

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

30 October 2018

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849770

30 October 2018

Characterization of circulating tumor cells by fluorescence in situ hybridization

1 reference

https://pubmed.ncbi.nlm.nih.gov/20159823

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20159823

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.24.6819

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33770374&oldid=2186406477"